Pilot Production of SARS-CoV-2 Related Proteins in Plants: A Proof of Concept for Rapid Repurposing of Indoor Farms Into Biomanufacturing Facilities
Autor: | Asun Fernández-del-Carmen, Rubén Mateos-Fernández, Marta Vazquez-Vilar, Diego Orzaez, Beatriz González, Borja Diego-Martin, Sara Selma, Silvia Gianoglio |
---|---|
Přispěvatelé: | European Commission, Ministerio de Economía y Competitividad (España), Generalitat Valenciana, Orzáez, Diego [0000-0003-1662-5403], Orzáez, Diego |
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
0106 biological sciences medicine.drug_class Computer science Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Plantmade antigen Nicotiana benthamiana Context (language use) Plant Science Computational biology lcsh:Plant culture Monoclonal antibody 01 natural sciences law.invention Synthetic biology 03 medical and health sciences law medicine Biomanufacturing lcsh:SB1-1110 Plant-made antigen Repurposing Original Research 030304 developmental biology 2. Zero hunger 0303 health sciences biology SARS-CoV-2 fungi COVID-19 biology.organism_classification Biofactories Molecular farming 030104 developmental biology Proof of concept Recombinant DNA 010606 plant biology & botany Plant-made antibody |
Zdroj: | Frontiers in Plant Science, Vol 11 (2020) bioRxiv Frontiers in Plant Science Digital.CSIC. Repositorio Institucional del CSIC instname |
Popis: | Disponible también versión preprint: http://hdl.handle.net/10261/221118 The current CoVid-19 crisis is revealing the strengths and the weaknesses of the world’s capacity to respond to a global health crisis. A critical weakness has resulted from the excessive centralization of the current biomanufacturing capacities, a matter of great concern, if not a source of nationalistic tensions. On the positive side, scientific data and information have been shared at an unprecedented speed fuelled by the preprint phenomena, and this has considerably strengthened our ability to develop new technology-based solutions. In this work, we explore how, in a context of rapid exchange of scientific information, plant biofactories can serve as a rapid and easily adaptable solution for local manufacturing of bioreagents, more specifically recombinant antibodies. For this purpose, we tested our ability to produce, in the framework of an academic lab and in a matter of weeks, milligram amounts of six different recombinant monoclonal antibodies against SARS-CoV-2 in Nicotiana benthamiana. For the design of the antibodies, we took advantage, among other data sources, of the DNA sequence information made rapidly available by other groups in preprint publications. mAbs were engineered as single-chain fragments fused to a human gamma Fc and transiently expressed using a viral vector. In parallel, we also produced the recombinant SARS-CoV-2 N protein and the receptor binding domain (RBD) of the Spike protein in planta and used them to test the binding specificity of the recombinant mAbs. Finally, for two of the antibodies, we assayed a simple scale-up production protocol based on the extraction of apoplastic fluid. Our results indicate that gram amounts of anti-SARS-CoV-2 antibodies could be easily produced in little more than 6 weeks in repurposed greenhouses with little infrastructure requirements using N. benthamiana as production platform. Similar procedures could be easily deployed to produce diagnostic reagents and, eventually, could be adapted for rapid therapeutic responses. This work was supported by H2020 EU projects 760331 Newcotiana and 774078 PharmaFactory. SS is recipient of a FPI fellowship BIO2016–78601-R from the Spanish Ministry of Science and Competitiveness and RM-F is recipient of a GVA fellowship (ACIF/2019/226). |
Databáze: | OpenAIRE |
Externí odkaz: |